Calcitriol treatment attenuates inflammation and oxidative stress in hemodialysis patients with secondary hyperparathyroidism

Chia Cha Wu, Jen Hung Chang, Chun Chi Chen, Shih Bin Su, Lai King Yang, Wen Ya Ma, Cai Mei Zheng, Liang Kuang Diang, Kuo Cheng Lu

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Hemodialysis patients with secondary hyperparathyroidism (SHP) suffer from excessive oxidative stress and inflammation. Vitamin D analogues are currently the first line therapy for SHP, but the influence of vitamin D treatment on inflammation and oxidative stress remains unknown. This study investigated the influence of vitamin D therapy on oxidative stress and inflammatory markers in hemodialysis patients with SHP. Twenty-five patients (mean age 58 ± 12 years, 13 males and 12 females) were enrolled in the study to receive calcitriol treatment for 16 weeks. We evaluated changes in the serum biochemical parameters, inflammatory markers [C-reactive protein (CRP) and interleukin-6 (IL-6) levels], serum oxidative stress condition [total antioxidant status (TAS)], and CD4+ T-lymphocyte intracellular cytokines [interferon γ (IFN-γ) and interleukin-4 (IL-4)] before and at the end of the 16-week calcitriol treatment. Correlations between each of these factors were also studied. All patients with SHP had low serum 1,25-dihydroxyvitamin D3 levels and elevated serum levels of intact parathyroid hormone (iPTH), CRP and IL-6. Twenty patients (10 males and 10 females) responded to the calcitriol therapy, with significant decrements in serum iPTH. Our results showed that calcitriol can effectively suppress iPTH secretion, reduce inflammatory markers (CRP and IL-6) and oxidative stress. It can also effectively reduce inflammatory cytokine (CD4+ IFN-γ) and increase anti-inflammatory cytokine (CD4+ IL-4). Interestingly, significant correlations between CD4+ IFN-γ levels and serum iPTH levels, as well as between TAS and iPTH levels were noted. Overall, our study has demonstrated calcitriol treatment significantly attenuates inflammation and oxidative stress in hemodialysis patients with SHP.

Original languageEnglish
Pages (from-to)153-159
Number of pages7
JournalTohoku Journal of Experimental Medicine
Volume223
Issue number3
DOIs
Publication statusPublished - 2011
Externally publishedYes

Fingerprint

Secondary Hyperparathyroidism
Oxidative stress
Calcitriol
Renal Dialysis
Parathyroid Hormone
Oxidative Stress
Inflammation
Vitamin D
C-Reactive Protein
Serum
Interleukin-6
Cytokines
Interleukin-4
Therapeutics
Antioxidants
T-cells
Interferons
Anti-Inflammatory Agents
T-Lymphocytes

Keywords

  • Calcitriol
  • Interferon-γ
  • Interleukin-4
  • Secondary hyperparathyroidism
  • Total anti-oxidative status

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Calcitriol treatment attenuates inflammation and oxidative stress in hemodialysis patients with secondary hyperparathyroidism. / Wu, Chia Cha; Chang, Jen Hung; Chen, Chun Chi; Su, Shih Bin; Yang, Lai King; Ma, Wen Ya; Zheng, Cai Mei; Diang, Liang Kuang; Lu, Kuo Cheng.

In: Tohoku Journal of Experimental Medicine, Vol. 223, No. 3, 2011, p. 153-159.

Research output: Contribution to journalArticle

Wu, Chia Cha ; Chang, Jen Hung ; Chen, Chun Chi ; Su, Shih Bin ; Yang, Lai King ; Ma, Wen Ya ; Zheng, Cai Mei ; Diang, Liang Kuang ; Lu, Kuo Cheng. / Calcitriol treatment attenuates inflammation and oxidative stress in hemodialysis patients with secondary hyperparathyroidism. In: Tohoku Journal of Experimental Medicine. 2011 ; Vol. 223, No. 3. pp. 153-159.
@article{f594143046514aa9a53519ef5be254db,
title = "Calcitriol treatment attenuates inflammation and oxidative stress in hemodialysis patients with secondary hyperparathyroidism",
abstract = "Hemodialysis patients with secondary hyperparathyroidism (SHP) suffer from excessive oxidative stress and inflammation. Vitamin D analogues are currently the first line therapy for SHP, but the influence of vitamin D treatment on inflammation and oxidative stress remains unknown. This study investigated the influence of vitamin D therapy on oxidative stress and inflammatory markers in hemodialysis patients with SHP. Twenty-five patients (mean age 58 ± 12 years, 13 males and 12 females) were enrolled in the study to receive calcitriol treatment for 16 weeks. We evaluated changes in the serum biochemical parameters, inflammatory markers [C-reactive protein (CRP) and interleukin-6 (IL-6) levels], serum oxidative stress condition [total antioxidant status (TAS)], and CD4+ T-lymphocyte intracellular cytokines [interferon γ (IFN-γ) and interleukin-4 (IL-4)] before and at the end of the 16-week calcitriol treatment. Correlations between each of these factors were also studied. All patients with SHP had low serum 1,25-dihydroxyvitamin D3 levels and elevated serum levels of intact parathyroid hormone (iPTH), CRP and IL-6. Twenty patients (10 males and 10 females) responded to the calcitriol therapy, with significant decrements in serum iPTH. Our results showed that calcitriol can effectively suppress iPTH secretion, reduce inflammatory markers (CRP and IL-6) and oxidative stress. It can also effectively reduce inflammatory cytokine (CD4+ IFN-γ) and increase anti-inflammatory cytokine (CD4+ IL-4). Interestingly, significant correlations between CD4+ IFN-γ levels and serum iPTH levels, as well as between TAS and iPTH levels were noted. Overall, our study has demonstrated calcitriol treatment significantly attenuates inflammation and oxidative stress in hemodialysis patients with SHP.",
keywords = "Calcitriol, Interferon-γ, Interleukin-4, Secondary hyperparathyroidism, Total anti-oxidative status",
author = "Wu, {Chia Cha} and Chang, {Jen Hung} and Chen, {Chun Chi} and Su, {Shih Bin} and Yang, {Lai King} and Ma, {Wen Ya} and Zheng, {Cai Mei} and Diang, {Liang Kuang} and Lu, {Kuo Cheng}",
year = "2011",
doi = "10.1620/tjem.223.153",
language = "English",
volume = "223",
pages = "153--159",
journal = "Tohoku Journal of Experimental Medicine",
issn = "0040-8727",
publisher = "Tohoku University Medical Press",
number = "3",

}

TY - JOUR

T1 - Calcitriol treatment attenuates inflammation and oxidative stress in hemodialysis patients with secondary hyperparathyroidism

AU - Wu, Chia Cha

AU - Chang, Jen Hung

AU - Chen, Chun Chi

AU - Su, Shih Bin

AU - Yang, Lai King

AU - Ma, Wen Ya

AU - Zheng, Cai Mei

AU - Diang, Liang Kuang

AU - Lu, Kuo Cheng

PY - 2011

Y1 - 2011

N2 - Hemodialysis patients with secondary hyperparathyroidism (SHP) suffer from excessive oxidative stress and inflammation. Vitamin D analogues are currently the first line therapy for SHP, but the influence of vitamin D treatment on inflammation and oxidative stress remains unknown. This study investigated the influence of vitamin D therapy on oxidative stress and inflammatory markers in hemodialysis patients with SHP. Twenty-five patients (mean age 58 ± 12 years, 13 males and 12 females) were enrolled in the study to receive calcitriol treatment for 16 weeks. We evaluated changes in the serum biochemical parameters, inflammatory markers [C-reactive protein (CRP) and interleukin-6 (IL-6) levels], serum oxidative stress condition [total antioxidant status (TAS)], and CD4+ T-lymphocyte intracellular cytokines [interferon γ (IFN-γ) and interleukin-4 (IL-4)] before and at the end of the 16-week calcitriol treatment. Correlations between each of these factors were also studied. All patients with SHP had low serum 1,25-dihydroxyvitamin D3 levels and elevated serum levels of intact parathyroid hormone (iPTH), CRP and IL-6. Twenty patients (10 males and 10 females) responded to the calcitriol therapy, with significant decrements in serum iPTH. Our results showed that calcitriol can effectively suppress iPTH secretion, reduce inflammatory markers (CRP and IL-6) and oxidative stress. It can also effectively reduce inflammatory cytokine (CD4+ IFN-γ) and increase anti-inflammatory cytokine (CD4+ IL-4). Interestingly, significant correlations between CD4+ IFN-γ levels and serum iPTH levels, as well as between TAS and iPTH levels were noted. Overall, our study has demonstrated calcitriol treatment significantly attenuates inflammation and oxidative stress in hemodialysis patients with SHP.

AB - Hemodialysis patients with secondary hyperparathyroidism (SHP) suffer from excessive oxidative stress and inflammation. Vitamin D analogues are currently the first line therapy for SHP, but the influence of vitamin D treatment on inflammation and oxidative stress remains unknown. This study investigated the influence of vitamin D therapy on oxidative stress and inflammatory markers in hemodialysis patients with SHP. Twenty-five patients (mean age 58 ± 12 years, 13 males and 12 females) were enrolled in the study to receive calcitriol treatment for 16 weeks. We evaluated changes in the serum biochemical parameters, inflammatory markers [C-reactive protein (CRP) and interleukin-6 (IL-6) levels], serum oxidative stress condition [total antioxidant status (TAS)], and CD4+ T-lymphocyte intracellular cytokines [interferon γ (IFN-γ) and interleukin-4 (IL-4)] before and at the end of the 16-week calcitriol treatment. Correlations between each of these factors were also studied. All patients with SHP had low serum 1,25-dihydroxyvitamin D3 levels and elevated serum levels of intact parathyroid hormone (iPTH), CRP and IL-6. Twenty patients (10 males and 10 females) responded to the calcitriol therapy, with significant decrements in serum iPTH. Our results showed that calcitriol can effectively suppress iPTH secretion, reduce inflammatory markers (CRP and IL-6) and oxidative stress. It can also effectively reduce inflammatory cytokine (CD4+ IFN-γ) and increase anti-inflammatory cytokine (CD4+ IL-4). Interestingly, significant correlations between CD4+ IFN-γ levels and serum iPTH levels, as well as between TAS and iPTH levels were noted. Overall, our study has demonstrated calcitriol treatment significantly attenuates inflammation and oxidative stress in hemodialysis patients with SHP.

KW - Calcitriol

KW - Interferon-γ

KW - Interleukin-4

KW - Secondary hyperparathyroidism

KW - Total anti-oxidative status

UR - http://www.scopus.com/inward/record.url?scp=79952408949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952408949&partnerID=8YFLogxK

U2 - 10.1620/tjem.223.153

DO - 10.1620/tjem.223.153

M3 - Article

C2 - 21350317

AN - SCOPUS:79952408949

VL - 223

SP - 153

EP - 159

JO - Tohoku Journal of Experimental Medicine

JF - Tohoku Journal of Experimental Medicine

SN - 0040-8727

IS - 3

ER -